|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 55511th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anita Drummond |
Date | 4/22/2019 8:40:27 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2019 and FY 2020 federal appropriations for: The Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment; and, issues regarding future work and funding of the CDC tobacco work. FY 2020 federal appropriations for: cancer research and prevention funding at the NIH, NCI and CDC.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), State - Dept of (DOS), Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), U.S. Agency for International Development (USAID)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:
HR 1570 and S. 668, the Removing Barriers to Colorectal Cancer Screening Act, and regulatory issues related to the Medicare coinsurance issue in these bills;
States Achieve Medicaid Expansion (SAME) Act, S. 585, to ensure states receive the same matching funds regardless of when they expand their Medicaid program;
Lymphedema Treatment Act, HR 1948, on Medicare reimbursement for supplies needed by lymphedema patients;
CMS-issued regulations pertaining to Medicare Part B reimbursement;
Draft legislation on establishment of Medicaid reimbursement for patient navigation;
Medicaid covering routine care costs for beneficiaries who participate in an approved clinical trial;
Issues related to Medicare coverage for BCRA testing and preventive surgery;
Issues related to utilization management in Medicare Part D plans;
Potential legislation for lowering prescription drug costs and lowering out of pocket costs for Medicare beneficiaries; and
CMS proposed regulatory changes on the six protected classes policy within the Medicare Part D prescription drug benefit.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Krenrich |
|
|
|
Phylicia |
Woods |
|
|
|
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:
Implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation;
Issues relating to FDA regulation of electronic cigarettes and cigars;
H.R.1854 & S.9, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act;
H.R. 2084, the Stopping Consumption of Tobacco by Teens Act of 2019;
H.R. 2111 and S. 1048, The Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act, and issues regarding age of sale of tobacco products;
Issues related to FDA tobacco control to be considered in House and Senate in the FY20 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation;
Issues related to tobacco taxes, flavored tobacco products, and online sale of tobacco products, H.R. 293, Youth Vaping Prevention Act of 2019; and
Issues related to smoke-free policies for the Veterans Health Administration.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues regarding expanding the availability of the charitable deduction for non-itemizers and issues respecting charitable giving and life income planning and issues respecting the medical expense deduction.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, clinical trials, skin cancer, and wellness, including:
HR 1010, to provide that the short-term rule has no force or effect;
HR 986 & S 466, Protecting Americans with Pre-Existing Conditions Act;
HR 1425, State Health Care Premium Reduction Act;
HR 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019;
HR 1884, Protecting Pre-Existing Conditions & Making Health Care More Affordable Act of 2019;
HR 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019;
Issues relating to curbing health care costs;
Issues related to surprise medical billing;
H.R.647, the Palliative Care and Hospice Education and Training Act;
Issues related to Breast Density and Mammography Reporting;
H.R.820 & S.292, the Childhood Cancer STAR Act;
Anti-cancer medication cost-sharing parity respecting H.R. 1409;
A national family caregiving strategy respecting S. 1719 and H.R. 1028;
Access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017;
Issues relating to FDA regulation of laboratory tests, Verifying Accurate Leading-edge IVCT Development Act of 2018 or the VALID Act of 2018;
H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018;
Caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act;
H. Res. 282, supporting initiatives to encourage parents and guardians to take measures to prevent sunburns in minors they care for;
H.R. 1966 & S 946, the Henrietta Lacks Enhancing Cancer Research Act of 2019, regarding decreasing disparities in access to cancer clinical trials;
Additional issues related to reducing disparities in cancer clinical trials;
Issues related to improving quality of life for cancer survivorship;
H.R. 2222 and S. 1107, the Women and Lung Cancer Research and Preventative Services Act; and
H.R. 1730 and S. 741, the Cancer Drug Parity Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), State - Dept of (DOS), White House Office, Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Denys |
Symonette |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia |
Woods |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |